Neuronetics Reports Impressive Third Quarter Financial Results
In its latest financial report for the third quarter of 2025, Neuronetics, Inc. (NASDAQ: STIM) has shown significant growth, achieving a total revenue of $37.3 million. This figure marks an 11% increase compared to the same period in 2024 when compared on an adjusted pro forma basis, and an astonishing 101% increase year-over-year on an unadjusted basis. Such performance reflects the company’s strategic direction and operational efficiencies, which have become increasingly vital in today's evolving health care landscape.
Key Highlights of Third Quarter Results
One of the standout metrics for Neuronetics this quarter is the revenue generated from the Greenbrook clinics, which totaled $21.8 million. This represents a robust 25% growth on an adjusted pro forma basis when compared with the third quarter of 2024. This remarkable increase is significantly attributed to the recent acquisitions that have expanded the company’s footprint in the neurohealth sector.
The third quarter report highlighted ongoing improvement in cash management, with only $0.8 million used in operations. Moreover, Neuronetics strengthened its balance sheet, concluding the quarter with $34.5 million in total cash, which includes cash, cash equivalents, and restricted cash. This cash reserve is a clear indication of the company's ability to sustain operations and invest in future growth.
Operational Efficiency and Milestones
During this period, the company achieved a momentous milestone, treating over 229,429 global patients with approximately 8.2 million treatment sessions. This not only validates Neuronetics' position within the therapy market but also emphasizes the demand for mental health solutions, particularly those provided by their NeuroStar Advanced Therapy System.
Furthermore, New York State Medicaid has expanded coverage for Transcranial Magnetic Stimulation (TMS) therapy, including NeuroStar Advanced Therapy, which aims at treating patients diagnosed with Major Depressive Disorder (MDD). This expansion is a testament to the growing recognition of TMS as an effective, non-pharmaceutical treatment for mental health disorders.
Continued Financial Growth and Funding Strategy
In August, Neuronetics secured an additional $10 million in funding through its debt agreement with Perceptive Credit Holdings IV, LP. The funds are designated for furthering their operational and growth strategies, particularly following the successful acquisition of Greenbrook TMS. This funding was contingent on reaching specific revenue milestones, and its extension will foster liquidity assurance through September 2026.
The company also raised $7.8 million through the sale of around 2.3 million shares of common stock under its at-the-market (ATM) facility. The proceeds will primarily fund general corporate purposes, supporting Neuronetics' ongoing initiatives in transforming mental health treatment with innovative technologies.
Future Outlook: Solid Projections for 2025
Looking ahead, Neuronetics anticipates promising prospects for the fourth quarter of 2025, with projected total worldwide revenue between $40 million and $43 million. For the full year, the revenue forecast sits between $147 million and $150 million. Gross margin expectations have also been adjusted to a range of 47% to 49% due to shifting business dynamics.
The company’s objectives include targeting positive cash flow from operations in the upcoming quarter, estimating a range of $2 million of positive to $2 million of negative operating cash flow. By year-end 2025, total cash, including cash equivalents and restricted cash, is projected between $32 million and $36 million, further securing Neuronetics' financial health.
Leadership Transition: Preparing for the Future
In a significant announcement, Neuronetics disclosed that CEO Keith J. Sullivan plans to retire effective June 30, 2026. The company has initiated a search for his successor to ensure continuity and stability during this transition. Mr. Sullivan, having been instrumental in the company’s evolution, especially following the strategic acquisition of Greenbrook TMS, is set to assist during the transition phase as a consultant.
Rob Cascella, Chairman of the Board at Neuronetics, expressed appreciation for Mr. Sullivan’s dedication and visionary leadership over the years, particularly highlighting his role in navigating the company through critical development phases. The Board is confident that the ongoing search will identify a leader committed to fostering future growth.
Conclusion: Neuronetics at the Forefront of Mental Health Treatment
Neuronetics continues to position itself as a pivotal player in the realm of neurohealth. With significant achievements in revenue, strategic acquisitions, and a clear vision for the future, the company is set to make impactful strides in mental health treatment. As we look forward to seeing how Neuronetics responds to the ever-changing landscape of healthcare, it is clear that they are taking steps to solidify their position and continue their commitment to improving patient outcomes.
Frequently Asked Questions
What were Neuronetics' third-quarter revenue figures for 2025?
Neuronetics reported third-quarter revenue of $37.3 million for 2025, marking an 11% increase compared to the same period in 2024.
How did the acquisition of Greenbrook contribute to Neuronetics' growth?
The acquisition of Greenbrook significantly enhanced Neuronetics' revenue streams, particularly contributing $21.8 million in clinic revenue during the third quarter of 2025.
What financial developments occurred for Neuronetics in 2025?
Neuronetics secured an additional $10 million in funding and raised $7.8 million through share sales to support operational and growth initiatives.
When is the CEO of Neuronetics expected to retire?
Keith J. Sullivan plans to retire as CEO on June 30, 2026, and will assist in the transition to his successor.
What does the future outlook look like for Neuronetics?
Neuronetics anticipates fourth-quarter revenue between $40 million and $43 million and a full-year revenue projection of $147 million to $150 million for 2025.
